Idrabiotaparinux | biotinylated idraparinux | CAS#774531-07-6 | inhibitor | factor Xa

MedKoo Cat#: 125415 | Name: Idrabiotaparinux

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Idrabiotaparinux, a biotinylated idraparinux, was developed as a long-acting inhibitor of factor Xa.

Chemical Structure

Idrabiotaparinux

CAS#774531-07-6 (free base)

Theoretical Analysis

MedKoo Cat#: 125415

Name: Idrabiotaparinux

CAS#: 774531-07-6 (free base)

Chemical Formula: C53H88N4O51S8

Exact Mass: 1852.2200

Molecular Weight: 1853.74

Elemental Analysis: C, 34.34; H, 4.79; N, 3.02; O, 44.02; S, 13.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

774531-07-6 (free base) 405159-59-3 (sodium)

Synonym

Idrabiotaparinux; UNII-H44R6RJT3S; 774531-07-6; H44R6RJT3S; IDRABIOTAPARINUX

IUPAC/Chemical Name

(2S,3S,4S,5R,6R)-6-(((2R,3R,4S,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-carboxy-4,5-dimethoxy-6-(((2R,3R,4S,5R,6S)-6-methoxy-4,5-bis(sulfooxy)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-3-yl)oxy)-4,5-bis(sulfooxy)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-(((2R,3R,4R,5S,6R)-4,5-dimethoxy-3-(6-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)hexanamido)-6-((sulfooxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dimethoxytetrahydro-2H-pyran-2-carboxylic acid

InChi Key

MUQWDYYIYNYBQD-OFHININYSA-N

InChi Code

InChI=1S/C53H88N4O51S8/c1-86-30-22(17-93-110(65,66)67)96-48(29(33(30)87-2)56-27(59)15-9-8-12-16-54-26(58)14-11-10-13-25-28-21(20-109-25)55-53(64)57-28)101-36-34(88-3)42(90-5)50(103-40(36)46(60)61)100-32-24(19-95-112(71,72)73)98-52(45(108-116(83,84)85)39(32)106-114(77,78)79)102-37-35(89-4)43(91-6)51(104-41(37)47(62)63)99-31-23(18-94-111(68,69)70)97-49(92-7)44(107-115(80,81)82)38(31)105-113(74,75)76/h21-25,28-45,48-52H,8-20H2,1-7H3,(H,54,58)(H,56,59)(H,60,61)(H,62,63)(H2,55,57,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76)(H,77,78,79)(H,80,81,82)(H,83,84,85)/t21-,22+,23+,24+,25-,28-,29+,30+,31+,32+,33+,34-,35-,36-,37-,38-,39-,40-,41+,42+,43+,44+,45+,48+,49-,50+,51+,52+/m0/s1

SMILES Code

[H][C@]12CS[C@@H](CCCCC(=O)NCCCCCC(=O)N[C@H]3[C@@H](O[C@@]4([H])[C@H](OC)[C@@H](OC)[C@H](O[C@]5([H])[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]6([H])[C@H](OC)[C@@H](OC)[C@H](O[C@]7([H])[C@@H](COS(O)(=O)=O)O[C@H](OC)[C@H](OS(O)(=O)=O)[C@H]7OS(O)(=O)=O)O[C@H]6C(O)=O)[C@H](OS(O)(=O)=O)[C@H]5OS(O)(=O)=O)O[C@@H]4C(O)=O)O[C@H](COS(O)(=O)=O)[C@@H](OC)[C@@H]3OC)[C@@]1([H])NC(=O)N2

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,853.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Song Y, Li X, Pavithra S, Li D. Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013 Nov 20;8(11):e78972. doi: 10.1371/journal.pone.0078972. PMID: 24278113; PMCID: PMC3835858. 2: Harenberg J. Idraparinux and idrabiotaparinux. Expert Rev Clin Pharmacol. 2010 Jan;3(1):9-16. doi: 10.1586/ecp.09.55. PMID: 22111528. 3: Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost. 2009 Nov;102(5):811-5. doi: 10.1160/TH09-08-0555. PMID: 19888513. 4: Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun;12(6):824-30. doi: 10.1111/jth.12546. PMID: 24597472. 5: Eikelboom JW, Weitz JI. Idrabiotaparinux treatment for venous thromboembolism. Lancet. 2012 Jan 14;379(9811):96-8. doi: 10.1016/S0140-6736(11)61580-8. Epub 2011 Nov 27. PMID: 22127297. 6: Lim GB. Anticoagulation therapy: Idrabiotaparinux noninferior to warfarin for long-term treatment of pulmonary embolism. Nat Rev Cardiol. 2011 Dec 13;9(2):68. doi: 10.1038/nrcardio.2011.201. PMID: 22158081. 7: Paty I, Trellu M, Destors JM, Cortez P, Boëlle E, Sanderink G. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost. 2010 Apr;8(4):722-9. doi: 10.1111/j.1538-7836.2010.03746.x. Epub 2010 Jan 17. PMID: 20088937. 8: Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost. 2011 Jan;9(1):92-9. doi: 10.1111/j.1538-7836.2010.04100.x. PMID: 20946157.